I personally don't believe AZ is working on dep-docetaxel with SPL.
I think the game plan for SPL is to churn out a quick (haha) Phase 2, maybe 12-18 months for the indications they desire, and own all the data post Phase 2. I think at that juncture they will then choose to license dep-docetaxel for the Phase 3.
I would much prefer them to take it all the way to market themselves, but at this point in time, they simply don't have the resources to do so.
Value - a tough one to work out, page-20
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $50.17M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 11.0¢ | $127.2K | 1.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 130918 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 103000 | 3 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |